In comparison to the other antihyperglycemic medications, GLP-1R agonists have established an increased capability to target directly or indirectly six out of the eight core defects (the ‘ominous octet’) associated with T2DM [11,12,13]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.